Trial Profile
Phase I/II, Open-Label Study of R-ICE (Rituximab-Ifosfamide-Carboplatin-Etoposide) With Lenalidomide (R2-ICE) in Patients With First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 16 Jan 2023
Price :
$35
*
At a glance
- Drugs Carboplatin (Primary) ; Etoposide (Primary) ; Ifosfamide (Primary) ; Lenalidomide (Primary) ; Rituximab (Primary)
- Indications B-cell lymphoma; Diffuse large B cell lymphoma
- Focus Adverse reactions; Therapeutic Use
- 31 Jan 2022 Status changed from recruiting to active, no longer recruiting.
- 05 Jan 2022 Planned primary completion date changed from 20 Oct 2021 to 20 Oct 2022.
- 19 Jul 2021 Planned primary completion date changed from 20 Apr 2021 to 20 Oct 2021.